
    
      Protection of endothelial dysfunction by intravenous infusion of Defibrotide (Defitelio),
      expected to decrease inflammation and expression of adhesion molecules in the endothelium,
      leukocyte tissue infiltration and epithelial destruction, and to promote immune tolerance
      through a change in the Cytokine balance, which is decisive in preventing multiorgan failure
      and death in patients with SARS-CoV-2 infection with clinical status grade 4, 5 or 6
      according to the WHO classification
    
  